CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Abroad (travel likely)RecruitingPHASE1
Conditions
Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Myelodysplastic Syndrome · Refractory Acute Myeloid Leukemia · Refractory Chronic Myelomonocytic Leukemia · Refractory Mixed Phenotype Acute Leukemia · Refractory Myelodysplastic Syndrome · Refractory Acute Leukemia of Ambiguous Lineage · Refractory Acute Undifferentiated Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Filippo Milano)
Study leads
Filippo Milano
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium